Michael Peyton

13.9k citations

57 papers · 5.7k indexed · 2 hit papers · h-index 35

Impact in

Sensory Systems top 0.2%
- Ion Channels and Receptors
Oncology top 2%
- HER2/EGFR in Cancer Research

Papers in

Molecular Biology 39
- Genomics and Chromatin Dynamics 7
- PI3K/AKT/mTOR signaling in cancer 6
- Protein Degradation and Inhibitors 5
- RNA modifications and cancer 5
- Histone Deacetylase Inhibitors Research 4
Oncology 15
- HER2/EGFR in Cancer Research 4

Co-authors: John D. Minna Lutz Birnbaumer Meisheng Jiang Luc Girard Guylain Boulay Adi F. Gazdar Enrico Stefani Xi Zhu
Journals: Cancer Research (13 papers)Proceedings of the National Academy of Sciences (4 papers)Journal of Thoracic Oncology (3 papers)PLoS ONE (3 papers)Neoplasia (2 papers)
Partner nations: United States Japan Australia

In The Last Decade

Michael Peyton

56 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance 2013 · 425 citations

Peers

Countries citing papers authored by Michael Peyton

Since Specialization

Citations

This map shows the geographic impact of Michael Peyton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Peyton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Peyton more than expected).

Fields of papers citing papers by Michael Peyton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Peyton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Peyton. The network helps show where Michael Peyton may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Peyton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Peyton Line = papers co-authored together Michael Peyton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Improper data practices erode the quality of global ecological databases and impede the progress of ecological research Global Change Biology ·杉島寛, जगदेव, 李洁琼, Esther O. Ekezie, Michael Peyton	2024	9
2	Dietary Niche Variation in an Invasive Omnivore: The Effects of Habitat on Feral Pig Resource Use in Hawai‘i Ecology and Evolution ·Michael Peyton, Kealohanuiopuna Kinney, Sarah Knox, D C Weaver, Sara C. Hotchkiss	2024	0
3	Feral pig (Sus scrofa) disturbance facilitates establishment of resource‐acquisitive species in Hawaiian forest understories Functional Ecology ·Michael Peyton, Samyak Sabannawar, Sara C. Hotchkiss	2023	3
4	Abstract 2690: In vivo CRISPR screen identifies SOAT1 as a chemotherapy chemosensitizing target for non-small cell lung cancer (NSCLC) Cancer Research ·Long Shan Li, Kenneth E. Huffman, Huiyu Li, Michael Peyton, Hyunsil Park, Léa Degorce, Luc Girard, Mathew M. Augustine, Joshua T. Mendell, John D. Minna	2023	1
5	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations Cancer Research ·Paul Yenerall, Rahul K. Kollipara, Léa Degorce, Michael Peyton, Christopher A. Eide, Daniel Bottomly, Shannon K. McWeeney, Yan Liu, Kenneth D. Westover, Brian Druker, John D. Minna, Ralf Kittler	2021	6
6	SLC43A3 Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2′-Deoxyguanosine Cancer Research ·Jianlei Chen, Kimberly Batten, Michael Peyton, Khanif Y. M, Crystal Cornelius, Luc Girard, Boning Gao, John D. Minna, Jerry W. Shay	2020	9
7	Telomerase-Mediated Strategy for Overcoming Non–Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance Neoplasia ·İlgen Mender, C.X. Liu, Krishna Luitel, Michael Peyton, Luc Girard, Tsung‐Po Lai, Kimberly Batten, Crystal Cornelius, Maithili P. Dalvi, Michael E. Ramirez, Wenting Du, Lani F. Wu, Steven J. Altschuler, Rolf A. Brekken, Luis Cerrillo, John D. Minna, Woodring E. Wright, Jerry W. Shay	2018	48
8	3D Spheroid/Organoid Models of Lung Cancer to Study Lung Cancer Pathogenesis and Testing of New Therapeutics Journal of Thoracic Oncology ·Bo Gao, Michael Peyton, Chao‐Yuan Huang, Tea Teppo, Luc Girard, Noah Sorrelle, 松坂ひとみ, Rolf A. Brekken, Adi F. Gazdar, John D. Minna	2017	2
9	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers Nature Communications ·Samira Zahmatbar, Shuguang Wei, Wei Zhang, Rolf A. Brekken, Bruce A. Posner, Michael Peyton, Luc Girard, Sergio Auricchio, David A. Wheeler, John D. Minna, Michael A. White, Adi F. Gazdar, Michael G. Roth	2017	81
10	PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis Cancer Research ·Xiaorong Zhou, Barrett L. Updegraff, Yabin Guo, Michael Peyton, Luc Girard, Jill E. Larsen, Xian‐Jin Xie, K. De Vis, Tae Hyun Hwang, Yang Xie, Jaime Rodriguez‐Canales, Pamela Villalobos, Carmen Behrens, Ignacio I. Wistuba, John D. Minna, Kathryn A. O’Donnell	2016	56
11	Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Molecular Cancer Therapeutics ·David E. Gerber, Puja Gupta, Michael T. Dellinger, Jason E. Toombs, Michael Peyton, Inga Duignan, L NORO, Timothy L. Bailey, A. Kartakoulis, Rolf A. Brekken, Nick Loizos	2012	35
12	Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy Molecular Cancer Therapeutics ·Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori, John D. Minna	2011	135
13	STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17 Cancer Research ·Bingbing Dai, Jieru Meng, Michael Peyton, Luc Girard, William G. Bornmann, Lin Ji, John D. Minna, Bingliang Fang, Jack A. Roth	2011	80
14	SMAC Mimetic (JP1201) Sensitizes Non–Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-α–Independent Manner Cancer Research ·A.A Alfaro, Michael Peyton, Jill E. Larsen, Luc Girard, Yang Xie, Adi F. Gazdar, Patrick G. Harran, Lai Wang, Rolf A. Brekken, Xiaodong Wang, John D. Minna	2011	48
15	Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation Cancer Research ·Di Cai, David S. Shames, Maria Gabriela Raso, Yang Xie, Young Ho Kim, Jonathan R. Pollack, Luc Girard, James P. Sullivan, Boning Gao, Michael Peyton, Meera Nanjundan, Lauren A. Byers, John V. Heymach, Gordon B. Mills, Adi F. Gazdar, Ignacio I. Wistuba, Thomas Kodadek, John D. Minna	2010	48
16	Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis American Journal Of Pathology ·Elisa Benedettini, Lynette M. Sholl, Michael Peyton, John F. Reilly, Christopher Ware, Lenora J. Davis, Natalie Vena, D. R. Shackleton Bailey, Beow Y. Yeap, Michelangelo Fiorentino, Azra H. Ligon, 薛殿凯, Victoria M. Richon, John D. Minna, Adi F. Gazdar, Giulio Draetta, Silvano Bòsari, Lucian R. Chirieac, Bart Lutterbach, Massimo Loda	2010	139
17	Protection Against Chronic Pancreatitis and Pancreatic Fibrosis in Mice Overexpressing Pancreatic Secretory Trypsin Inhibitor Pancreas ·Jaimie D. Nathan, Joelle Romac, Ruth Y. Peng, Michael Peyton, Don C. Rockey, Rodger A. Liddle	2009	26
18	MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors International Journal of Cancer ·Takafumi Kubo, Hiromasa Yamamoto, William W. Lockwood, Mikhail Vlasov, Junichi Soh, Michael Peyton, Masaru Jida, Hiroki Otani, Tetsuya Fujii, Mamoru Ouchida, Nagio Takigawa, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, John D. Minna, Marileila Varella‐Garcia, Wan L. Lam, Adi F. Gazdar, Shinichi Toyooka	2008	117
19	Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis Cancer Cell ·Urve Tellas, Lai Wang, Wessels Lm, Lin Li, Michael Peyton, John D. Minna, Patrick G. Harran, Xiaodong Wang	2007	473
20	Non–Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation Cancer Research ·Amit Kumar Das, Mitsuo Sato, Michael D. Story, Michael Peyton, Robert J. Graves, Stella Redpath, Luc Girard, Adi F. Gazdar, Jerry W. Shay, John D. Minna, Chaitanya S. Nirodi	2006	178

About Michael Peyton

Michael Peyton is a scholar working on Molecular Biology, Oncology, Cancer Research, Physiology and Pulmonary and Respiratory Medicine, having authored 57 papers that have together received 5.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Genomics and Chromatin Dynamics (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Protein Degradation and Inhibitors (5 papers), RNA modifications and cancer (5 papers), Histone Deacetylase Inhibitors Research (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Sensory Systems (1.1k citations), Oncology (1.5k citations), Molecular Biology (3.5k citations), Cancer Research (754 citations) and Cellular and Molecular Neuroscience (747 citations). Michael Peyton has collaborated with scholars based in United States, Japan and Australia. Frequent co-authors include John D. Minna, Lutz Birnbaumer, Meisheng Jiang, Luc Girard, Guylain Boulay, Adi F. Gazdar, Enrico Stefani, Xi Zhu, Xiangcheng Zhu and Xiaodong Wang. Their work appears in journals such as Cancer Research, Proceedings of the National Academy of Sciences, Journal of Thoracic Oncology, PLoS ONE and Neoplasia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact